Pharmafile Logo

News and Press Releases

Santhera Announces Approval in Canada for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only approved therapy for DMD...

Category: Other, Pharmaceutical
Posted: October 3, 2025

Santhera
office@santhera.com
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

AGAMREE® is approved by MHRA for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in UK 14 January 2025 -- Pratteln, Switzerland -- Santhera Pharmaceuticals...

Category: Other, Pharmaceutical
Posted: January 14, 2025

Santhera
office@santhera.com
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland

Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group

6 January 2025 -- Pratteln, Switzerland -- Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE (vamorolone) in countries...

Category: Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: January 6, 2025

Santhera
office@santhera.com
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland

Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only...

Category: Other, Pharmaceutical
Posted: December 11, 2024

Santhera
office@santhera.com
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland

Santhera Receives Positive Recommendation from NICE for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern Ireland Santhera will be working...

Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024

Santhera
office@santhera.com
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland

Scotland first in the UK to recommend a new treatment option for lung cancer, which could help lower the risk of cancer returning

7 October 2024 -- Scotland, UK -- the Scottish Medicines Consortium has recommended MSD's KEYTRUDA® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma (NSCLC)...

Category: Other, Pharmaceutical
Posted: October 7, 2024

Scottish Medicines Consortium
Delta House 50 West Nile Street Glasgow G1 2NP

GSK’s Omjjara▼ (momelotinib) is accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia

Clinicians in Scotland will now have the option to use momelotinib for the treatment of disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia Momelotinib is...

Category: Other, Pharmaceutical
Posted: June 10, 2024

GSK
980 Great West Rd, London TW8 9GS

GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting

Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...

Category: Pharmaceutical
Posted: April 8, 2024

Scottish Medicines Consortium (SMC) accepts Camzyos▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy

Mavacamten has been accepted for use within NHS Scotland for the treatment of symptomatic(New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy(HCM) in adult patients. HCM is...

Category: Pharmaceutical
Posted: April 8, 2024

Bristol Myers Squibb (BMS)
medical.information@bms.com
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH

Scottish Medicines Consortium accepts Sotyktu(deucravacitinib) for NHS use in certain adults with moderate to severe plaque psoriasis

Deucravacitinib has been accepted by the Scottish Medicines Consortium (SMC) for use in Scotland for the treatment of adults with moderate to severe plaque psoriasis who are eligible for systemic...

Category: Pharmaceutical
Posted: December 11, 2023

Bristol Myers Squibb (BMS)
medical.information@bms.com
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH